Hepatitis C
Conditions
Keywords
rosuvastatin, hepatitis C, geranylgeranylation, HCV-RNA load
Brief summary
Objective: Determine if maximum doses of rosuvastatin are safe in patients infected with hepatitis C and if the so called pleiotropic effects of rosuvastatin cause a decrease in the HCV viral load. Primary study parameters: 1. to which extend causes rosuvastatin serious side effects like rhabdomyolysis and hepatotoxicity in patients chronically infected with hepatitis C? 2. does treatment with rosuvastatin in HCV infected patients lead to lower HCV-RNA viral load? 3. Is a decrease in LDL correlated to a decrease in HCV-RNA load?
Detailed description
Study design: it's a pilot study in which the patients form their own control group. A total of 10 patients will be included. To evaluate the effect of maximum doses of rosuvastatin on liver function and side effects, first 2 patients will be treated and evaluated. If they experience no serious adverse events then a further 8 patients will be included. The dose of rosuvastatin will be increased over a period of 4 weeks. Intervention: based on experience in treating dyslipidemia, gradually increasing the dose of rosuvastatin diminishes the experienced side effects and decreases the chances of developing hepatotoxicity. Therefore in this study we chose to increase the dose (see flowchart). Patients will start with 5 mg a day wich will be increased after 1 week to 10 mg per day. After the second week of therapy a further increase to 20 mg per day is executed. This dose will be given for another 2 weeks. At week 4 of treatment a further increase to 40 mg is done.
Interventions
DRUGrosuvastatin
Sponsors
UMC Utrecht
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* age between 18 and 65 years * All patients with hepatitis C (all genotypes) * negative for hepatitis B and HIV * ALAT \< 2,5 x below the upper limit of normal * serological evidence of hepatitis C infection with detectable HCV-RNA (with Bayer Versant HCV bDNA V3.0) * failed current standard of care treatment with peginterferon and ribavirin * WHO-score ≤1 * fertile women must have a negative pregnancy test in the week before start of medication. Use of contraceptives during the whole study-period * physically and mentally able to attend outpatients clinics
Exclusion criteria
* Hepatitis C patiënts naive for (peg)interferon and ribavirin treatment * Alcohol abuses (\> 20 grams per day) in the last year * liver cirrhosis detected through liver biopsy or decompensated liver disease (child-pugh B or C) * concomitant treatment with hepatotoxic medication / interfering with CYP450 system: anti-fungal medication (voriconazole), antibiotics (gentamycine, azitromycine, claritromycin, erytromycin), immuun-suppresive drugs (cyclosporine), anti-arythmia (diltiazem, verapamil) and tuberculostatic drugs (rifampicin). * current statin use * active pregnancy or wish of pregnangy * use of grapefruit juice * mentally not fit to participate in the study * daily use of more than 2 grams of paracetamol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| occurrence of serious side effects like rhabdomyolysis and hepatotoxicity during treatment | — |
| decrease of HCV-RNA viral load during treatment | — |
| decrease of LDL during treatment | — |
Countries
Netherlands
Outcome results
None listed